- USO significantly reduces high-grade serous ovarian cancer risk by 36% compared to controls.
- The study included 42,306 women under 50 from Swedish registries.
- USO does not increase the risk of coronary artery disease or osteoporosis.
- Follow-up median time was 13 years, confirming consistency of results.
- Findings specific to premenopausal women under 50.
- Limitations include unavailability of certain confounding factors.
- USO could serve as an alternative to BSO for cancer prevention.
Source: PLOS Medicine